 Precigen Inc NASDAQ: PGEN presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 11b study of PRGN-3006 UltraCAR-T in relapsed or refractory rr acute myeloid leukemia and higher-risk myelodysplastic syndromes. PRGN-3006 UltraCAR-T is a multigenic autologous CAR-T simultaneously expressing a CAR targeting CD33. 